$VIRX
Viracta Therapeutics, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019030130 Filed on August 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2 2018 Q1
Revenue $0.00 $0.00 $240.0K
YoY Change -64.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.520M $2.820M $3.360M
YoY Change -10.64% -23.16% -14.72%
% of Gross Profit
Research & Development $3.680M $3.760M $3.969M
YoY Change -2.13% -23.89% -35.57%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $2.000K
YoY Change
% of Gross Profit
Operating Expenses $6.210M $6.582M $3.969M
YoY Change -5.65% -23.57% -60.7%
Operating Profit -$6.206M -$6.582M -$7.091M
YoY Change -5.71% -23.57%
Interest Expense $111.0K $287.0K $281.0K
YoY Change -61.32% -16.57% -158.54%
% of Operating Profit
Other Income/Expense, Net $76.00K $29.00K $99.00K
YoY Change 162.07% -74.56% 10.0%
Pretax Income -$6.240M -$6.840M -$7.270M
YoY Change -8.77% -22.62% -26.04%
Income Tax
% Of Pretax Income
Net Earnings -$6.241M -$6.840M -$7.273M
YoY Change -8.76% -22.64% -26.01%
Net Earnings / Revenue -3030.42%
Basic Earnings Per Share
Diluted Earnings Per Share -$3.029M -$6.980M -$7.418M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2018 Q2 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.20M $20.40M $25.40M
YoY Change -40.2% -10.13% -27.84%
Cash & Equivalents $9.797M $17.03M $21.37M
Short-Term Investments $2.400M $3.400M $4.000M
Other Short-Term Assets $7.700M $1.500M $1.500M
YoY Change 413.33% 87.5% 114.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $19.84M $21.90M $26.90M
YoY Change -9.4% -6.81% -25.07%
LONG-TERM ASSETS
Property, Plant & Equipment $7.000K $0.00 $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $105.0K $100.0K $100.0K
YoY Change 5.0% -92.86%
Total Long-Term Assets $1.202M $100.0K $100.0K
YoY Change 1102.0% -92.86%
TOTAL ASSETS
Total Short-Term Assets $19.84M $21.90M $26.90M
Total Long-Term Assets $1.202M $100.0K $100.0K
Total Assets $21.04M $22.00M $27.00M
YoY Change -4.35% -11.65% -24.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $692.0K $1.600M $1.000M
YoY Change -56.75% -30.43% -61.54%
Accrued Expenses $2.600M $3.200M $3.300M
YoY Change -18.75% 6.67% -21.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.500M $7.300M $7.300M
YoY Change -24.66% 329.41% 58.7%
Total Short-Term Liabilities $8.743M $12.00M $11.60M
YoY Change -27.14% 71.43% 1.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $17.00K $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $17.00K $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.743M $12.00M $11.60M
Total Long-Term Liabilities $17.00K $0.00 $0.00
Total Liabilities $9.305M $12.00M $11.60M
YoY Change -22.46% -3.23% -46.3%
SHAREHOLDERS EQUITY
Retained Earnings -$671.6M
YoY Change
Common Stock $7.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.74M $9.975M $15.37M
YoY Change
Total Liabilities & Shareholders Equity $21.04M $22.00M $27.00M
YoY Change -4.35% -11.65% -24.77%

Cashflow Statement

Concept 2019 Q2 2018 Q2 2018 Q1
OPERATING ACTIVITIES
Net Income -$6.241M -$6.840M -$7.273M
YoY Change -8.76% -22.64% -26.01%
Depreciation, Depletion And Amortization $0.00 $0.00 $2.000K
YoY Change
Cash From Operating Activities -$6.900M -$5.900M -$6.550M
YoY Change 16.95% -45.42% -32.19%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$2.390M $640.0K $740.0K
YoY Change -473.44% -94.96% -93.17%
Cash From Investing Activities -$2.390M $640.0K $742.0K
YoY Change -473.44% -94.95% -93.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -240.0K 920.0K 196.0K
YoY Change -126.09% -155.09% -91.25%
NET CHANGE
Cash From Operating Activities -6.900M -5.900M -6.550M
Cash From Investing Activities -2.390M 640.0K 742.0K
Cash From Financing Activities -240.0K 920.0K 196.0K
Net Change In Cash -9.530M -4.340M -5.612M
YoY Change 119.59% -2270.0% -264.57%
FREE CASH FLOW
Cash From Operating Activities -$6.900M -$5.900M -$6.550M
Capital Expenditures $0.00
Free Cash Flow -$5.900M
YoY Change -45.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
000-51531
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9797000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13696000
CY2019Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
5500000
CY2019Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2386000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2159000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1504000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
19842000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
15200000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1090000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
105000
dei Entity Central Index Key
EntityCentralIndexKey
0001061027
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Registrant Name
EntityRegistrantName
SUNESIS PHARMACEUTICALS INC
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
California
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei Trading Symbol
TradingSymbol
SNSS
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
943295878
dei Entity Address Address Line1
EntityAddressAddressLine1
395 Oyster Point Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
266-3500
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
76000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6183000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
113000
CY2019Q2 us-gaap Assets
Assets
21044000
CY2018Q4 us-gaap Assets
Assets
15324000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
692000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1393000
CY2019Q2 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
525000
CY2018Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
500000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
869000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
943000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
656000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1091000
CY2019Q2 us-gaap Notes Payable Current
NotesPayableCurrent
5456000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7396000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8743000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11323000
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
545000
CY2019Q2 us-gaap Liabilities
Liabilities
9305000
CY2018Q4 us-gaap Liabilities
Liabilities
11331000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
7113000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
20998000
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
676189000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
642460000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-671570000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-659469000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
11739000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3993000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21044000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15324000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
237000
CY2019Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7727000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4962000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
6582000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11893000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2019Q2 us-gaap Interest Expense
InterestExpense
111000
CY2018Q2 us-gaap Interest Expense
InterestExpense
287000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2386000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1382000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5453000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7500000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
7879000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10662000
CY2018Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72190000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34417000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65702000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34381000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Profit Loss
ProfitLoss
-12101000
us-gaap Profit Loss
ProfitLoss
-14113000
us-gaap Share Based Compensation
ShareBasedCompensation
811000
us-gaap Share Based Compensation
ShareBasedCompensation
1548000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
107000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
96000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
647000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-984000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-701000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-144000
snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
25000
snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-215000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-74000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-485000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-431000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-121000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13007000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12446000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2386000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1382000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
464000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
851000
snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
36000
snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
264000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16994000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1115000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1601000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9949000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13696000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26977000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15297000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17028000
us-gaap Stock Issued1
StockIssued1
448000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
21762000
snss Legal Expenses Accrued As Cost Of Equity Financing
LegalExpensesAccruedAsCostOfEquityFinancing
-5000
snss Legal Expenses Accrued As Cost Of Equity Financing
LegalExpensesAccruedAsCostOfEquityFinancing
-125000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
9975000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
17086000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
15365000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21544000
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16551000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16551000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s condensed consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, debt instruments, revenue recognition, stock-based compensation, ROU assets, lease liabilities, and clinical trial accounting. </p>
CY2019Q2 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
2386000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10845000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10845000
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10845000
CY2019Q2 snss Cash And Cash Equivalents Restricted Cash And Marketable Securities
CashAndCashEquivalentsRestrictedCashAndMarketableSecurities
17700000
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15097000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15097000
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
11044000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
11044000
CY2019Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8658000
CY2019Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8658000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
652000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10845000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2018 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019Q2 us-gaap Notes Payable
NotesPayable
5500000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
394000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
811000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1548000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
1400000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
285000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
578000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
294000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1157000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
67000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1090000
CY2019Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2018Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000

Files In Submission

Name View Source Status
0001564590-19-030130-index-headers.html Edgar Link pending
0001564590-19-030130-index.html Edgar Link pending
0001564590-19-030130.txt Edgar Link pending
0001564590-19-030130-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ghxa003qubzu000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10q_20190630.htm Edgar Link pending
snss-20190630.xml Edgar Link completed
snss-20190630.xsd Edgar Link pending
snss-20190630_cal.xml Edgar Link unprocessable
snss-20190630_def.xml Edgar Link unprocessable
snss-20190630_lab.xml Edgar Link unprocessable
snss-20190630_pre.xml Edgar Link unprocessable
snss-ex311_6.htm Edgar Link pending
snss-ex312_7.htm Edgar Link pending
snss-ex321_8.htm Edgar Link pending